Person:
KISKAÇ, MUHARREM

Loading...
Profile Picture
Status
Kurumdan Ayrılmıştır.
Organizational Units
Organizational Unit
Job Title
First Name
MUHARREM
Last Name
KISKAÇ
Name
Email Address
Birth Date

Search Results

Now showing 1 - 10 of 48
  • PublicationOpen Access
    CD40 ligand and P-selectin in heterozygous Beta-thalassemia
    (2016-06-01) CIKRIKCIOGLU, Mehmet Ali; SOYTAS, Rabia Bag; KILIC, Elif; Toprak, Aybala Erek; Karatoprak, CUMALİ; Zorlu, MEHMET; Kiskac, MUHARREM; EMEGIL, Sebnem; Cetin, GÜVEN; Dogan, ELİF ECE; SEKIN, Yahya; HAMDARD, Jamshid; ÇAKIRCA, MUSTAFA; ZORLU, MEHMET; KISKAÇ, MUHARREM; ÇETİN, GÜVEN; DOĞAN, ELİF ECE; KARATOPRAK, CUMALİ
    Objective: To investigate platelet functions and measure soluble CD40 ligand, soluble P-selectin, beta-thromboglobulin and platelet factor 4 levels in the blood of heterozygous beta thalassemia patients. Methods: The cross-sectional case-control study was conducted at Bezmialem Vakif University, Istanbul, Turkey, between September 2013 and April 2014, and comprised heterozygous beta thalassemia patients who were compared with 41 gender-, age- and body mass index-matched controls for platelet function markers. The two groups were also compared for co-morbidities, smoking, and regular medications. Results: Of the 78(78.78) subjects, 50(64%) were women and 28(36%) men with an overall mean age of 39.4±12.7 years (range: 18-79 years). The mean body mass index was 26.3±4.2. The heterozygous beta thalassemia group included 37(47%) subjects [24(65%) females; 13(35%) males] while the control group had 41(53%) [26(63%) females; 15(37%) males]. Soluble CD40 ligand and soluble P-selectin were lower in the heterozygous beta thalassemia group (p=0.009; p=0.010). Beta-thromboglobulin and platelet factor 4 levels were comparable between the groups (p=0.497; p=0.507.). Conclusions: Some platelet functions may be reduced in heterozygous beta thalassemia patients, which may be related to their lower incidence of cerebral and cardiac ischaemic events.
  • PublicationOpen Access
    Serum endocan levels in women with restless legs syndrome.
    (2015-11-19) CELIK, K; ÇıKRıKÇıOĞLU, MA; HALAC, G; KILIC, ERDEM; AYHAN, S; OZARAS, N; Karatoprak, CUMALİ; YILDIZ, KEMALETTİN; YILDIZ, RS; ZORLU, MEHMET; CAKIRCA, MUSTAFA; KıSKAÇ, MUHARREM; KILIÇ, ERDEM; YILDIZ, KEMALETTİN; ZORLU, MEHMET; KARATOPRAK, CUMALİ; ÇAKIRCA, MUSTAFA; KISKAÇ, MUHARREM
    Background: Endocan is a recently introduced marker of endothelial dysfunction. The objective of this study was to compare serum endocan levels in patients with restless legs syndrome (RLS) and control subjects in order to elucidate whether RLS is associated with endothelial dysfunction. Methods: A total of 31 drug naïve female patients with RLS and 31 age- and BMI-matched women were included in the study. Patients with pathological or physiological conditions or with a history of medication use that could potentially influence endothelial functions were excluded, as well as those with alcohol or drug abuse history. The two groups were compared with routine blood tests and serum endocan levels. Results: Patients with RLS had lower serum endocan levels than the controls (P=0.037). There was a negative bivariate correlation between RLS severity score and serum endocan levels (r=-0.406, P=0.023). While white blood cell count was significantly higher in RLS group, 25-hydroxy vitamin D3, vitamin B12, transferrin saturation rate, and HDL-cholesterol were significantly lower. Creatininemia and diastolic blood pressure were also marginally insignificantly lower in RLS group. Due to the presence of differences between two groups in these variables, a linear regression analysis was performed that showed a positive association between endocan and creatininemia (β=0.310, P=0.022), and a negative association between endocan and RLS (β=-0.502, P,0.001). Conclusion: The results of this study seem to suggest that patients with RLS may have better endothelial functions when compared with the general population and that these patients may be better protected against atherosclerosis
  • PublicationMetadata only
    Evaluation of the relationship between vitamin D level and adropin, IL-1β, IL-6, and oxidative status in women
    (2022-01-01T00:00:00Z) ZORLU, MEHMET; ŞEKERCİ, ABDÜSSELAM; TUNÇ, MUHAMMED; Güler, Eray Metin; Gülen, Bedia; KARATOPRAK, CUMALİ; KISKAÇ, MUHARREM; ÇAKIRCA, MUSTAFA; ZORLU, MEHMET; ŞEKERCİ, ABDÜSSELAM; TUNÇ, MUHAMMED; KARATOPRAK, CUMALİ; KISKAÇ, MUHARREM; ÇAKIRCA, MUSTAFA
    Background: Vitamin D, adropin, proinflammatory cytokines, and oxidative stress closely related with metabolic homeostasis and endothelial dysfunction. The aim of the present study is to investigate how vitamin D levels affect serum adropin, IL-1ß, IL-6, and oxidative stress. Methods: A total of 77 female subjects were divided into 3 groups according to vitamin D levels. Biochemical parameters, adropin, IL-1ß, IL-6, oxidative stress markers were studied in these groups, and the results were compared statistically. Results: Serum adropin, IL-1ß, IL-6, total oxidant status (TOS) and total antioxidant status (TAS) and oxidative stress index (OSI) levels differed significantly between the vitamin D groups (p < 0.05). A significant positive correlation was detected between vitamin D, and adropin and TAS (r = 0.807; p < 0.001, r = 0.814; p < 0.001, respectively). A significant negative correlation was detected between vitamin D, and IL-1ß, IL-6, TOS, OSI (r = -0.725; p < 0.001, r = -0.720; p < 0.001, r = -0.238; p = 0.037, r = -0.705; p < 0.001, respectively). Discussion: Vitamin D could show its effects through vitamin D receptors on tissues or on the ENHO gene in adropin secreting tissues via direct or indirect mechanisms. Proinflammatory cytokines, oxidative stress, and adropin targeted studies could contribute to the prevention and treatment of diseases associated with vitamin D deficiency in future.
  • PublicationOpen Access
    Association of calcium channel blocker use with lower hemoglobin levels in chronic kidney disease
    (2013-09-01) Karatoprak, CUMALİ; CIKRIKCIOGLU, M. A.; Cakirca, MUSTAFA; Kiskac, MUHARREM; Zorlu, MEHMET; Cetin, GÜVEN; YILDIZ, KEMALETTİN; ERKOC, R.; ALAY, M.; Erkal, S.; Erkal, S. N.; DOGAN, S.; Kazancioglu, RÜMEYZA; KARATOPRAK, CUMALİ; ÇAKIRCA, MUSTAFA; KISKAÇ, MUHARREM; ZORLU, MEHMET; ÇETİN, GÜVEN; YILDIZ, KEMALETTİN; KAZANCIOĞLU, RÜMEYZA
    Aim: To search whether calcium channel blockers (CCBs) are associated with lower hemoglobin levels in chronic kidney disease (CKD) patients who are not on renal replacement therapy (RRT), vitamin D and anti-anemic treatment. Patients and methods: CKD patients were classified into two groups. Patients on CCBs treatment (103 patients) and patients not using CCBs (104 patients) were compared cross-sectionally regarding clinical findings, complete blood count (CBC), biochemistry and regular medication use. Patients with polycystic kidney disease, comorbidities that could influence CBC other than iron deficiency of obscure origin, patients receiving RRT, erythropoietin (EPO), vitamin D, phosphate binders and drugs that could influence CBC were excluded. Under dependent variable of CCB use, all significantly different independent variables were subjected to multivariate binary logistic regression analysis (MBLRA). Results: Lower hemoglobin, lower bilirubinemia, higher serum EPO, higher systolic blood pressure were observed in CCB users. Two groups were similar concerning age, gender, BMI, CKD etiology, CKD stage, pretibial edema prevalence, cardiothoracic index, diastolic blood pressure, corrected reticulocyte count, BUN, creatinine, eGFR, proBNP, parathormone, alkaline phosphatase, phosphorous, corrected calcemia, sCRP, relative EPO deficiency and prevalence of relative EPO deficient patients. Groups were comparable regarding comorbidities, types and usage frequencies of all antihypertensive medications other than CCBs. Higher systolic blood pressure and lower hemoglobin were significantly associated with CCB use after MBLRA. Conclusions: Hemoglobin was significantly lower in CCB users compared to non-users, among CKD patients who did not receive RRT, EPO, phosphate binders, vitamin D, iron, vitamin B12 and folic acid.
  • PublicationMetadata only
    Diyabetik hastalarda diyetisyen kontrolü sıklığı bunun hasta memnuniyeti ve kan şeker regülasyonu üzerine etkisi
    (2011-05-15) KISKAÇ, MUHARREM; ÇAKIRCA, MUSTAFA; YOLBAŞ, SERVET; ÇIKRIKÇIOĞLU, MEHMET ALİ; ZORLU, MEHMET; BÜYÜKAYDIN, BANU; KISKAÇ, MUHARREM; ÇAKIRCA, MUSTAFA; ZORLU, MEHMET; BÜYÜKAYDIN, BANU
  • PublicationOpen Access
    Serum obestatin and omentin levels in patients with diabetic nephropathy
    (2017-02-01) ZORLU, MEHMET; KISKAC, MUHARREM; Gueler, ERAY METİN; GUELTEPE, I.; YAVUZ, E.; CELIK, K.; KOCYIGIT, ABDÜRRAHİM; ZORLU, MEHMET; KISKAÇ, MUHARREM; GÜLER, ERAY METİN; KOÇYİĞİT, ABDÜRRAHİM
    Introduction: Diabetic nephropathy is the leading cause of chronic kidney disease and accounts for almost 45% of all new patients requiring renal replacement therapy. Omentin and obestatin, two novel proteins were suggested to be associated with insulin resistance, type 2 diabetes and cardiovascular risk factors. Thus, we postulated that they may also have an association with diabetic nephropathy which is known to be an independent cardiovascular risk factor. In order to investigate such an association we compared serum omentin and obestatin levels in type 2 diabetic patients with normoalbuminuria (NA) and macroalbuminuria (MA). Materials and Methods: A total of 81 type 2 diabetic patients were separated into two groups according to their proteinuria status; patients with NA (n = 39) and patients with MA (n = 42). Two groups were compared in terms of serum omentin and obestatin levels. Results: While serum omentin levels did not differ among two groups (P = 0.407), serum obestatin levels were significantly higher in MA group (P = 0.001). Conclusion: The results of this study showed that higher serum levels of obestatin were associated with macro albuminuria suggesting that obestatin may have a role in underlying pathogenic mechanisms that leads to diabetic nephropathy
  • PublicationMetadata only
    Diyabetik hastaların kullandıkları ilaçları bilmelerinin HbA1c üzerine etkisi var mı
    (2011-05-15) ÇAKIRCA, MUSTAFA; KISKAÇ, MUHARREM; YOLBAŞ, SERVET; ZORLU, MEHMET; PERU, CELALETTİN; ÇIKRIKÇIOĞLU, MEHMET ALİ; ÇAKIRCA, MUSTAFA; KISKAÇ, MUHARREM; ZORLU, MEHMET
  • PublicationMetadata only
    Diyabetik Nefropatili Hastalarda Oksidatif Stresin Rolü
    (2016-03-21T00:00:00Z) Terzioğlu, Cemal; GÜLER, ERAY METİN; Uçak, Sinem; Çakmak, Orhan; ZORLU, MEHMET; KISKAÇ, MUHARREM; KOÇYİĞİT, ABDÜRRAHİM; GÜLER, ERAY METİN; ZORLU, MEHMET; KISKAÇ, MUHARREM; KOÇYİĞİT, ABDÜRRAHİM
  • PublicationMetadata only
    Diyabetik hastalardaki sigara kullanımı ve kan şekeri regülasyonu ile ilişkisi
    (2011-05-15) ZORLU, MEHMET; KISKAÇ, MUHARREM; YOLBAŞ, SERVET; ÇAKIRCA, MUSTAFA; BÜYÜKAYDIN, BANU; ZORLU, MEHMET; KISKAÇ, MUHARREM; ÇAKIRCA, MUSTAFA; BÜYÜKAYDIN, BANU
  • PublicationMetadata only
    A case of rhabdomyolysis complicated with acute renal failure after resumption of fenofibrate therapy: a first report.
    (2013-05-01) KıSKAÇ, MUHARREM; ZORLU, MEHMET; CAKIRCA, MUSTAFA; Karatoprak, CUMALİ; PERU, C; ERKOÇ, R; YAVUZ, E; KISKAÇ, MUHARREM; ZORLU, MEHMET; ÇAKIRCA, MUSTAFA; KARATOPRAK, CUMALİ